37261677|t|Safety outcomes of direct oral anticoagulants in older adults with atrial fibrillation: a systematic review and meta-analysis of (subgroup analyses from) randomized controlled trials.
37261677|a|Balancing stroke prevention and risk of bleeding in patients with atrial fibrillation (AF) is challenging. Direct oral anticoagulants (DOACs) are by now considered standard of care for treating patients with AF in international guidelines. Our objective was to assess the safety of long-term intake of DOACs in older adults with AF. We included RCTs in elderly (>= 65 years) patients with AF. A systematic search in MEDLINE and EMBASE was performed on 19 April 2022. For determination of risk of bias, the RoB 2 tool was applied. We pooled outcomes using random-effects meta-analyses. The quality of evidence was assessed using GRADE. Eleven RCTs with a total of 63,374 patients were identified. Two RCTs compared apixaban with either warfarin or aspirin, four edoxaban with either placebo, aspirin, or vitamin K antagonists (VKAs), two dabigatran with warfarin and three rivaroxaban with warfarin. DOACs probably reduce mortality in elderly patients with AF (HR 0.89 95%CI 0.77 to 1.02). Low-dose DOACs likely reduce bleeding compared to VKAs (HR ranged from 0.47 to 1.01). For high-dose DOACS the risk of bleeding varied widely (HR ranged from 0.80 to 1.40). We found that low-dose DOACs probably decrease mortality in AF patients. Moreover, apixaban and probably edoxaban are associated with fewer major or clinically relevant bleeding (MCRB) events compared to VKAs. For dabigatran and rivaroxaban, the risk of MCRB varies depending on dose. Moreover, subgroup analyses indicate that in the very old (>= 85) the risk for MCRB events might be increased when using DOACs.Registration: PROSPERO: CRD42020187876.
37261677	19	45	direct oral anticoagulants	Chemical	-
37261677	67	86	atrial fibrillation	Disease	MESH:D001281
37261677	194	200	stroke	Disease	MESH:D020521
37261677	224	232	bleeding	Disease	MESH:D006470
37261677	236	244	patients	Species	9606
37261677	250	269	atrial fibrillation	Disease	MESH:D001281
37261677	271	273	AF	Disease	MESH:D001281
37261677	291	317	Direct oral anticoagulants	Chemical	-
37261677	319	324	DOACs	Chemical	-
37261677	378	386	patients	Species	9606
37261677	392	394	AF	Disease	MESH:D001281
37261677	486	491	DOACs	Chemical	-
37261677	513	515	AF	Disease	MESH:D001281
37261677	559	567	patients	Species	9606
37261677	573	575	AF	Disease	MESH:D001281
37261677	854	862	patients	Species	9606
37261677	898	906	apixaban	Chemical	MESH:C522181
37261677	919	927	warfarin	Chemical	MESH:D014859
37261677	931	938	aspirin	Chemical	MESH:D001241
37261677	945	953	edoxaban	Chemical	MESH:C552171
37261677	975	982	aspirin	Chemical	MESH:D001241
37261677	987	1008	vitamin K antagonists	Chemical	-
37261677	1010	1014	VKAs	Chemical	-
37261677	1021	1031	dabigatran	Chemical	MESH:D000069604
37261677	1037	1045	warfarin	Chemical	MESH:D014859
37261677	1056	1067	rivaroxaban	Chemical	MESH:D000069552
37261677	1073	1081	warfarin	Chemical	MESH:D014859
37261677	1083	1088	DOACs	Chemical	-
37261677	1126	1134	patients	Species	9606
37261677	1140	1142	AF	Disease	MESH:D001281
37261677	1182	1187	DOACs	Chemical	-
37261677	1202	1210	bleeding	Disease	MESH:D006470
37261677	1223	1227	VKAs	Chemical	-
37261677	1273	1278	DOACS	Chemical	-
37261677	1291	1299	bleeding	Disease	MESH:D006470
37261677	1368	1373	DOACs	Chemical	-
37261677	1405	1407	AF	Disease	MESH:D001281
37261677	1408	1416	patients	Species	9606
37261677	1428	1436	apixaban	Chemical	MESH:C522181
37261677	1450	1458	edoxaban	Chemical	MESH:C552171
37261677	1514	1522	bleeding	Disease	MESH:D006470
37261677	1524	1528	MCRB	Disease	MESH:D004830
37261677	1549	1553	VKAs	Chemical	-
37261677	1559	1569	dabigatran	Chemical	MESH:D000069604
37261677	1574	1585	rivaroxaban	Chemical	MESH:D000069552
37261677	1599	1603	MCRB	Disease	MESH:D004830
37261677	1709	1713	MCRB	Disease	MESH:D004830
37261677	1751	1756	DOACs	Chemical	-
37261677	Cotreatment	MESH:D000069604	MESH:D014859
37261677	Negative_Correlation	MESH:D000069552	MESH:D001281
37261677	Negative_Correlation	MESH:C522181	MESH:D004830
37261677	Cotreatment	MESH:C522181	MESH:D014859
37261677	Positive_Correlation	MESH:D000069604	MESH:D004830
37261677	Negative_Correlation	MESH:C522181	MESH:D006470
37261677	Negative_Correlation	MESH:C552171	MESH:D004830
37261677	Positive_Correlation	MESH:D000069552	MESH:D004830
37261677	Negative_Correlation	MESH:C552171	MESH:D006470

